Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

低剂量放射疗法可逆转肿瘤免疫沙漠化和免疫治疗耐药性

阅读:3
作者:Fernanda G Herrera ,Catherine Ronet ,Maria Ochoa de Olza # ,David Barras # ,Isaac Crespo # ,Massimo Andreatta ,Jesus Corria-Osorio ,Aodrenn Spill ,Fabrizio Benedetti ,Raphael Genolet ,Angela Orcurto ,Martina Imbimbo ,Eleonora Ghisoni ,Blanca Navarro Rodrigo ,Dominik R Berthold ,Apostolos Sarivalasis ,Khalil Zaman ,Rafael Duran ,Clarisse Dromain ,John Prior ,Niklaus Schaefer ,Jean Bourhis ,Georgia Dimopoulou ,Zoi Tsourti ,Marius Messemaker ,Thomas Smith ,Sarah E Warren ,Periklis Foukas ,Sylvie Rusakiewicz ,Mikaël J Pittet ,Stefan Zimmermann ,Christine Sempoux ,Urania Dafni ,Alexandre Harari ,Lana E Kandalaft ,Santiago J Carmona ,Denarda Dangaj Laniti ,Melita Irving # ,George Coukos #

Abstract

Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell infiltration and enables responsiveness to combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive and innate immunity and depended on both cytotoxic CD4+ and CD8+ T cells. LDRT elicited predominantly CD4+ cells with features of exhausted effector cytotoxic cells, with a subset expressing NKG2D and exhibiting proliferative capacity, as well as a unique subset of activated dendritic cells expressing the NKG2D ligand RAE1. We translated these findings to a phase I clinical trial administering LDRT, low-dose cyclophosphamide, and immune checkpoint blockade to patients with immune-desert tumors. In responsive patients, the combinatorial treatment triggered T-cell infiltration, predominantly of CD4+ cells with Th1 signatures. Our data support the rational combination of LDRT with immunotherapy for effectively treating low T cell-infiltrated tumors. SIGNIFICANCE: Low-dose radiation reprogrammed the tumor microenvironment of tumors with scarce immune infiltration and together with immunotherapy induced simultaneous mobilization of innate and adaptive immunity, predominantly CD4+ effector T cells, to achieve tumor control dependent on NKG2D. The combination induced important responses in patients with metastatic immune-cold tumors.This article is highlighted in the In This Issue feature, p. 1.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。